These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8588056)

  • 41. A comparative study of suriclone, lorazepam and placebo in anxiety disorder.
    de Jonghe F; Swinkels J; Tuynman-Qua H; Jonkers F
    Pharmacopsychiatry; 1989 Nov; 22(6):266-71. PubMed ID: 2575766
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Buspirone: multicenter efficacy study.
    Wheatley D
    J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):92-4. PubMed ID: 6130079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks' treatment with diazepam or buspirone.
    Murphy SM; Owen R; Tyrer P
    Br J Psychiatry; 1989 Apr; 154():529-34. PubMed ID: 2686797
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder.
    Feltner DE; Harness J; Brock J; Sambunaris A; Cappelleri JC; Morlock R
    CNS Neurosci Ther; 2009; 15(1):12-8. PubMed ID: 19228175
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder.
    Feighner JP; Merideth CH; Hendrickson GA
    J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):103-8. PubMed ID: 6130066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Failure of buspirone to manage benzodiazepine withdrawal.
    Schweizer E; Rickels K
    Am J Psychiatry; 1986 Dec; 143(12):1590-2. PubMed ID: 2878622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Buspirone in the management of major depression: a placebo-controlled comparison.
    Fabre LF
    J Clin Psychiatry; 1990 Sep; 51 Suppl():55-61. PubMed ID: 2211570
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation.
    Romach MK; Kaplan HL; Busto UE; Somer G; Sellers EM
    J Clin Psychopharmacol; 1998 Apr; 18(2):121-31. PubMed ID: 9555597
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A risk-benefit assessment of buspirone in the treatment of anxiety disorders.
    Pecknold JC
    Drug Saf; 1997 Feb; 16(2):118-32. PubMed ID: 9067123
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of lorazepam on hypertension-associated anxiety: a double-blind study.
    Hart WL; Parmley LF
    J Clin Psychiatry; 1978 Oct; 39(10 Pt 2):41-5. PubMed ID: 30767
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study.
    Lee ST; Park JH; Kim M
    Headache; 2005 Sep; 45(8):1004-11. PubMed ID: 16109114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam.
    Herrera-Arellano A; Jiménez-Ferrer E; Zamilpa A; Morales-Valdéz M; García-Valencia CE; Tortoriello J
    Planta Med; 2007 Jul; 73(8):713-7. PubMed ID: 17562493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy.
    Udelman HD; Udelman DL
    J Clin Psychiatry; 1990 Sep; 51 Suppl():46-50. PubMed ID: 2211568
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical potential and possibilities of using buspirone in the treatment of anxiety disorders].
    Dzampaev AT; Suvorova IA; Damulin IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):94-104. PubMed ID: 25389538
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Behavioral and subjective effects of buspirone and lorazepam in sedative abusers: supra-therapeutic doses.
    Critchfield TS; Griffiths R
    NIDA Res Monogr; 1990; 105():318. PubMed ID: 1876027
    [No Abstract]   [Full Text] [Related]  

  • 56. A placebo-controlled trial of buspirone for the treatment of marijuana dependence.
    McRae-Clark AL; Carter RE; Killeen TK; Carpenter MJ; Wahlquist AE; Simpson SA; Brady KT
    Drug Alcohol Depend; 2009 Nov; 105(1-2):132-8. PubMed ID: 19699593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations.
    Fontaine R; Mercier P; Beaudry P; Annable L; Chouinard G
    Acta Psychiatr Scand; 1986 Nov; 74(5):451-8. PubMed ID: 2880459
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is imipramine or buspirone treatment effective in patients wishing to discontinue long-term benzodiazepine use?
    Sontheimer DL; Ables AZ
    J Fam Pract; 2001 Mar; 50(3):203. PubMed ID: 11252203
    [No Abstract]   [Full Text] [Related]  

  • 59. Clinical assessment of lorazepam in anxiety: a double-blind study.
    Olgiati SG
    Curr Ther Res Clin Exp; 1975 Jan; 17(1):13-22. PubMed ID: 237741
    [No Abstract]   [Full Text] [Related]  

  • 60. [Description of a patient with schizophrenia and coexisting megadose lorazepam dependence with slightly expressed withdrawl symptoms during drug reduction. A case report].
    Schylla A; Scisło P; Badura-Brzoza K; Pasierb N
    Wiad Lek; 2012; 65(4):243-6. PubMed ID: 23654146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.